#Neurology

Mubadala, CBC buy UCB neurology, allergy units

Abu Dhabi’s Mubadala co-invests in UCB’s neurology, allergy business

The deal, which is expected to close in Q4 2024, includes UCB’s neurology portfolio (Keppra, Vimpat, Neupro) and allergy medicines (Zyrtec, Xyzal)